This page contains a Flash digital edition of a book.
FEATURE


item, the leverage to control spiraling costs has basically vanished,” he says. “Add to this what some claim to be opportunistic ‘price gouging’ and our industry is vulnerable. Over the past few years, for example, an intravenous analgesic came to market as a single- source item for approximately $10 per dose. After witnessing volume traction and surge, today we see prices hover- ing around $30 per dose.”


Ezerskis adds, “Medication is now


usually my biggest line item for a case if there is no implant associated with the procedure.”


Manage Your Drug Supply


Effective ways to keep on top of shortages and costs BY ROBERT KURTZ


M


anaging her ASC’s medication inventory is not just an occa-


sional part of the job for Cheryl Ezer- skis, CASC, executive director at West Parkway Ambulatory Surgery Cen- ter in Pompton Plains, New Jersey. “I spend more time managing our inven- tory than I care to admit,” she says. “I have to monitor medications every day. Getting the medications we need to do our procedures is a never-ending game I have to play.”


ASCs throughout the country are


facing growing challenges with acquir- ing medications, says Christopher Dembny, president of Dembny Phar- macy Consultants in Richardson, Texas. “If you cannot get the drugs your patients need, you may have to cancel cases, and cases are the entire source of your revenue,” he says. “And since


18 ASC FOCUS MAY 2016


ASCs typically get paid by the case, if the cost of medications goes up, that usually comes directly out of the profit on the case.”


Across-the-Board Price Increases The rising cost of drugs is putting sig- nificant pressure on her ASC’s bottom line, Ezerskis says. “Not one medica- tion has gone down in price. Every- thing has gone up at least double since we started using it.” Medication


prices shift in the


marketplace for the same reasons as for most commodities, says Shel- don Sones, president of Sheldon S. Sones and Associates, a pharmacy and accreditation consulting firm based in Newington, Connecticut. “Whether it is supply and demand or the evolution of a single-source


Shortages Hit Hard A visit to the US Food and Drug Administration’s (FDA) web page on drug shortages (www.accessdata. fda.gov/scripts/drugshortages/default. cfm) and ASCA’s drug shortage page (www.ascassociation.org/drugshortages) reveals a significant number of drugs that have experienced a shortage, and the dozens still in short supply. Sones notes there are many causes for drug shortages, such as interruption of the supply chain of raw materials, unanticipated demand and manufacturers abandoning low-profit products. “The health care industry, and ASCs in particular, are highly vulnerable to this uncontrollable challenge,” he says. An “increase in regulatory enforce-


ment” by the FDA is another contribu- tor to the shortage, Sones points out. “That has been a double-edged sword. Increased enforcement can delay drugs from entering the supply chain, but it helps provide protection against com- promised products or products devel- oped through a compromised—or one thought to be—manufacturing practice from reaching facilities and patients.” When the quantity of available medications goes down, ASCs can expect to see prices head in the oppo- site direction, Dembny says. “If you have to buy the drug from a third-party or smaller wholesaler, it is probably


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34